Skip to main content

esketamine hydrochloride (Vesierra®)

 

Following non-submission

AWMSG advice

Status: Not endorsed (Statement of Advice)

In the absence of a submission from the holder of the marketing authorisation, esketamine hydrochloride (Vesierra®) cannot be endorsed for use within NHS Wales for the induction and maintenance of general anaesthesia, as the only anaesthetic or in combination with another anaesthetic, anesthesia and pain relief (analgesia) in emergency medicine and supplementation of regional or local anaesthesia.

 Statement of Advice (SOA): esketamine hydrochloride (Vesierra) 2337 (PDF, 186Kb)

Medicine details

Medicine name esketamine hydrochloride (Vesierra®)
Formulation 5 mg/ml solution for injection
Reference number 2337
Indication

Induction and maintenance of general anaesthesia, as the only anaesthetic or in combination with another anaesthetic, anesthesia and pain relief (analgesia) in emergency medicine and supplementation of regional or local anaesthesia

Company Pfizer Ltd
BNF chapter Anaesthesia
Assessment type Non-submission
Status Not endorsed (Statement of Advice)
Date of issue 06/12/2013
Follow AWTTC: